JP2020537649A5 - - Google Patents

Download PDF

Info

Publication number
JP2020537649A5
JP2020537649A5 JP2020520804A JP2020520804A JP2020537649A5 JP 2020537649 A5 JP2020537649 A5 JP 2020537649A5 JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020537649 A5 JP2020537649 A5 JP 2020537649A5
Authority
JP
Japan
Prior art keywords
seq
sequence
heavy chain
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020520804A
Other languages
English (en)
Japanese (ja)
Other versions
JP7374891B2 (ja
JP2020537649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/055733 external-priority patent/WO2019075417A1/en
Publication of JP2020537649A publication Critical patent/JP2020537649A/ja
Publication of JP2020537649A5 publication Critical patent/JP2020537649A5/ja
Priority to JP2023183034A priority Critical patent/JP2024012366A/ja
Application granted granted Critical
Publication of JP7374891B2 publication Critical patent/JP7374891B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020520804A 2017-10-14 2018-10-12 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法 Active JP7374891B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023183034A JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
US62/572,467 2017-10-14
PCT/US2018/055733 WO2019075417A1 (en) 2017-10-14 2018-10-12 CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023183034A Division JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Publications (3)

Publication Number Publication Date
JP2020537649A JP2020537649A (ja) 2020-12-24
JP2020537649A5 true JP2020537649A5 (enExample) 2021-07-26
JP7374891B2 JP7374891B2 (ja) 2023-11-07

Family

ID=64110112

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520804A Active JP7374891B2 (ja) 2017-10-14 2018-10-12 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法
JP2023183034A Pending JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023183034A Pending JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Country Status (36)

Country Link
US (3) US20190111150A1 (enExample)
EP (2) EP3834846A1 (enExample)
JP (2) JP7374891B2 (enExample)
KR (4) KR20230070046A (enExample)
CN (1) CN111278467B (enExample)
AR (1) AR115178A1 (enExample)
AU (1) AU2018346969A1 (enExample)
BR (1) BR112020007302B1 (enExample)
CA (1) CA3077730A1 (enExample)
CL (1) CL2020000977A1 (enExample)
CO (1) CO2020005685A2 (enExample)
CR (1) CR20200206A (enExample)
CY (1) CY1123968T1 (enExample)
DK (1) DK3691692T3 (enExample)
DO (1) DOP2023000150A (enExample)
EC (1) ECSP20025198A (enExample)
ES (1) ES2864013T3 (enExample)
HR (1) HRP20210436T8 (enExample)
HU (1) HUE054037T2 (enExample)
IL (1) IL273586A (enExample)
LT (1) LT3691692T (enExample)
MA (1) MA50752B1 (enExample)
MD (1) MD3691692T2 (enExample)
MX (1) MX2020003723A (enExample)
PE (1) PE20210125A1 (enExample)
PH (1) PH12020550417A1 (enExample)
PL (1) PL3691692T3 (enExample)
PT (1) PT3691692T (enExample)
RS (1) RS61596B1 (enExample)
RU (2) RU2022111211A (enExample)
SG (1) SG11202003378WA (enExample)
SI (1) SI3691692T1 (enExample)
SM (1) SMT202100184T1 (enExample)
TW (2) TW202330039A (enExample)
UY (1) UY37931A (enExample)
WO (1) WO2019075417A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
PE20210125A1 (es) * 2017-10-14 2021-01-19 Abbvie Inc Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
KR20220164773A (ko) * 2020-04-08 2022-12-13 앨리어다 테라퓨틱스, 인코포레이티드 혈액-뇌 장벽 전달용 조성물 및 방법
WO2021207657A1 (en) * 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
AU2021313058A1 (en) * 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
CA3226298A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4366774A4 (en) * 2021-07-09 2025-11-19 Dyne Therapeutics Inc MUSCLE TARGETTING COMPLEXES AND THEIR USES FOR MODULATING GENES ASSOCIATED WITH MUSCLE HEALTH
US20250332265A1 (en) 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
WO2025133132A1 (en) * 2023-12-20 2025-06-26 Institut National De La Sante Et De La Recherche Medicale Novel anti-tfr1 (cd71) antibodies for cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
WO2007027935A2 (en) 2005-08-31 2007-03-08 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
US8236318B2 (en) * 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
ES2725356T3 (es) * 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
WO2010129609A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
SG191977A1 (en) * 2011-02-01 2013-08-30 Genmab As Human antibodies and antibody-drug conjugates against cd74
HUE054362T2 (hu) * 2012-01-31 2021-09-28 Sbi Biotech Co Ltd Foszfolipáz D4 elleni antitest
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用
PE20210125A1 (es) * 2017-10-14 2021-01-19 Abbvie Inc Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos

Similar Documents

Publication Publication Date Title
HRP20210436T1 (hr) Konjugati protutijela s lijekom koje može aktivirati protutijelo protiv cd71 i postupci njihove upotrebe
JP2022064924A5 (enExample)
JP2020524661A5 (enExample)
JP2020500016A5 (enExample)
JP2020506900A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
MX2025004236A (es) Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana)
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
HRP20241563T1 (hr) Postupak liječenja ili ublažavanja metaboličkih poremećaja primjenom agonista glp-1 receptora konjugiranih na antagoniste želučanog inhibitornog peptidnog receptora (gipr)
JP2019504032A5 (enExample)
JP2022512234A5 (enExample)
RU2015101803A (ru) Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2020500538A5 (enExample)
JP2020519643A5 (enExample)
PE20140133A1 (es) Nuevas proteinas de union a antigenos
ME02807B (me) HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE
JP2021501579A5 (enExample)
JP2015120706A5 (enExample)
RU2014146503A (ru) Белки, связывающие антиген - лиганд cd30 человека
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
PE20071055A1 (es) Anticuerpos anti mn
NZ603972A (en) Anti-fgfr2 antibodies
RU2010116152A (ru) Антитело против рецептора il-6
JP2021533159A5 (enExample)